Literature DB >> 19229228

Elevated HbA1c level: a risk factor for cardiovascular disease mortality in patients with chronic heart failure?

Kay-Tee Khaw1.   

Abstract

This Practice Point commentary discusses a study by Gerstein et al. that found an independent relationship between HbA(1c) level and the risk of cardiovascular mortality, death from any cause, or worsening heart failure in patients with chronic heart failure. The magnitude of this risk increased by approximately 10-20% per 1% increase in HbA(1c) level. These findings add to a growing body of evidence that HbA(1c) levels predict cardiovascular disease mortality and morbidity in individuals with low, medium and high risks of cardiovascular disease. However, further research will be required to establish whether lowering HbA(1c) levels to <7% reduces the risk of cardiovascular events. Nevertheless, measurement of HbA(1c) level could identify and target effective therapies to individuals who are at high risk of cardiovascular disease. Improved understanding of the role of glycemic control in the development of cardiovascular disease might indicate new interventions for treatment and prevention.

Entities:  

Year:  2009        PMID: 19229228     DOI: 10.1038/ncpendmet1069

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN: 1745-8366


  7 in total

1.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

Review 2.  Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.

Authors:  Elizabeth Selvin; Shari Bolen; Hsin-Chieh Yeh; Crystal Wiley; Lisa M Wilson; Spyridon S Marinopoulos; Leonard Feldman; Jason Vassy; Renee Wilson; Eric B Bass; Frederick L Brancati
Journal:  Arch Intern Med       Date:  2008-10-27

3.  Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.

Authors:  Elizabeth Selvin; Spyridon Marinopoulos; Gail Berkenblit; Tejal Rami; Frederick L Brancati; Neil R Powe; Sherita Hill Golden
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

4.  10-year follow-up of intensive glucose control in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

5.  The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Authors:  Hertzel C Gerstein; Karl Swedberg; Jonas Carlsson; John J V McMurray; Eric L Michelson; Bertil Olofsson; Marc A Pfeffer; Salim Yusuf
Journal:  Arch Intern Med       Date:  2008-08-11

6.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

Review 7.  Glycated hemoglobin as a marker of cardiovascular risk.

Authors:  Kay-Tee Khaw; Nicholas Wareham
Journal:  Curr Opin Lipidol       Date:  2006-12       Impact factor: 4.776

  7 in total
  1 in total

1.  The influence of pharmacist-led adherence support on glycaemic control in people with type 2 diabetes.

Authors:  Mangesh Kharjul; Rhiannon Braund; James Green
Journal:  Int J Clin Pharm       Date:  2018-02-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.